Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Chromium picolinate→

Chromium Picolinate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
14639-25-9
PubChem CID
151932
Molecular formula
C18H12CrN3O6
Molecular weight
418.3 g/mol
Drug class
Trivalent chromium (Cr3+) nutritional supplementchromium picolinate complex
Mechanism of action
Provides trivalent chromium, a trace element proposed to influence insulin signalling and macronutrient metabolism. The molecular role of chromium in humans is incompletely defined, and clinical evidence for glycaemic benefit is inconsistent.
Indications / reported uses
  • Nutritional supplementation in selected patients with inadequate chromium intake; use for diabetes or weight loss is not an established universally approved therapeutic indication

Sources: NIH Office of Dietary Supplements — Chromium fact sheet · NLM MeSH — Chromium picolinate · FDA product information

Identification source: PubChem record (CID 151932). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Trivalent chromium (Cr3+) nutritional supplement; chromium picolinate complex

Mechanism of action

Provides trivalent chromium, a trace element proposed to influence insulin signalling and macronutrient metabolism. The molecular role of chromium in humans is incompletely defined, and clinical evidence for glycaemic benefit is inconsistent.

General use cases

  • Nutritional supplementation in selected patients with inadequate chromium intake; use for diabetes or weight loss is not an established universally approved therapeutic indication

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Chromium Picolinate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Chromium Picolinate Permitted Daily Exposure (PDE) report (the Chromium Picolinate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Chromium Picolinate Occupational Exposure Limit (OEL) report (the Chromium Picolinate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.